+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07004244

Study of mRNA Vaccine Targeting KRAS Mutations for Treating KRAS-Mutated Malignant Tumors

Led by Sichuan University · Updated on 2025-06-24

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of an mRNA vaccine targeting KRAS mutations in malignant tumors. KRAS mutations play a key role in the development and progression of various cancers such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Due to the difficulty in directly targeting KRAS proteins, this study explores mRNA vaccines as a promising new treatment option, either alone or combined with immune checkpoint inhibitors, to improve outcomes for patients with KRAS-mutated cancers. The study includes two groups one receiving escalating doses of the KRAS-mutated mRNA vaccine alone, and another receiving the vaccine combined with Toripalimab, pemetrexed, and carboplatin as a pre-surgery treatment. Participants in the combination group will undergo surgery after this neo-adjuvant treatment. The trial uses a non-randomized design and aims to assess the vaccines safety and immune response over several months. Participants will be monitored for adverse events for up to 12 months, and immune responses to the vaccine will be assessed for up to 7 months. Researchers will also measure tumor responses, progression-free survival, overall survival, and surgical feasibility. The study involves regular clinical assessments, laboratory tests, and imaging to evaluate treatment effects and safety throughout the participation period, which may last up to a year.

CONDITIONS

Brief Title

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here